AUNA S.A. Stock Price, News & Analysis

Auna (NYSE: AUNA) announced that it and Oncosalud will seek to privately offer senior secured notes due 2032 to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.

The Notes are expected to be fully and unconditionally guaranteed on a senior secured basis by certain subsidiaries. Proceeds will be used to (i) fund a tender offer to purchase any and all of its 10.000% Senior Secured Notes due 2029 and (ii) prepay indebtedness under the credit agreement dated November 10, 2023, plus related interest, fees and expenses. Timing, pricing and terms are subject to market conditions.

Auna (NYSE:AUNA) commenced a cash tender offer and consent solicitation for any and all of its outstanding 10.000% Senior Secured Notes due 2029, with U.S.$372,937,161 principal outstanding. The company is offering U.S.$1,070 per U.S.$1,000 principal (including a U.S.$50 early tender payment) for notes validly tendered by the Early Tender Date of October 31, 2025. The Tender Offer expires at 5:00 p.m. NY time on November 18, 2025, with expected early settlement on November 6, 2025 and final settlement on November 21, 2025. The purchase is conditioned on receiving majority consents and successful execution of a Proposed New Notes Offering and a Proposed Term Loan.

Auna (NYSE:AUNA), a Latin American healthcare provider, announced significant expansion of its OncoMexico insurance network through strategic partnerships with leading medical institutions across Mexico's major urban centers. The company has partnered with prominent healthcare facilities including Médica Sur in Mexico City, San Javier in Guadalajara, and Simnsa in Tijuana, among others.

The company plans to invest approximately US$500 million in Mexico's principal cities over the next 3-5 years. To fund this expansion and improve its capital structure, Auna will meet with debt and equity investors to explore financing options, aiming to maintain leverage at 3x Net Debt-to-EBITDA. Additionally, following its listing on the Lima Stock Exchange, Auna meets eligibility criteria for inclusion in three MSCI indices.

Auna (NYSE:AUNA), a leading Latin American healthcare platform, reported its Q2 2025 financial results with mixed performance. The company achieved 4% FX-neutral revenue growth to S/1,094 million, though reported revenue decreased 2% year-over-year due to currency headwinds. Adjusted EBITDA grew 5% FX-neutral to S/241 million, with margin holding steady at 22.1%.

Notable achievements include Adjusted Net Income of S/89 million, up significantly from S/13 million in Q2 2024, and a stable leverage ratio of 3.6x. The company demonstrated strong performance across its geographic segments, with local currency revenue growth of 5% in Mexico and 8% in Peru, while Colombia remained flat. The Oncology MLR reached a record low of 49.8%.

Auna (NYSE/BVL:AUNA), a leading healthcare services provider in Latin America, has initiated trading of its common shares on the Lima Stock Exchange (BVL), marking a significant expansion of its market presence. The company, which operates in Mexico, Peru, and Colombia, becomes the only healthcare company listed on the BVL.

This dual-listing strategy aims to enhance trading liquidity, strengthen Auna's presence in Latin American capital markets, and broaden access for local and regional investors. The company's shares will continue trading on both the NYSE and BVL under the ticker symbol "AUNA", potentially increasing its eligibility for inclusion in various equity indices and expanding its institutional investor base.

Auna (NYSE:AUNA), a leading Latin American healthcare services and plan provider operating in Mexico, Peru, and Colombia, has scheduled its Second Quarter 2025 financial results announcement.

The company will release its earnings on Tuesday, August 19, 2025 after market close, followed by a conference call on Wednesday, August 20, 2025 at 8:00 a.m. ET. A quiet period will be observed from August 4 through August 19, 2025.

Auna (NYSE: AUNA), a Latin American healthcare company operating in Mexico, Peru, and Colombia, announced that its controlling shareholder Enfoca has successfully refinanced its sponsor-level financing. The new facility extends the maturity date from October 5, 2025, to the end of June 2027, and includes improved economic terms for sponsors and pre-IPO shareholders.

Importantly, Auna is not a party to, does not guarantee, and has no liability regarding the debt under this new sponsor-level financing. The refinancing is expected to strengthen the long-term alignment between Auna and its pre-IPO shareholders while supporting the company's strategic growth initiatives in Spanish-speaking Latin America.

Auna (NYSE: AUNA), a Latin American healthcare platform, reported mixed Q1 2025 financial results. Consolidated Revenue decreased 3% YoY to S/1,042 million (though up 4% FXN), while Adjusted EBITDA fell 8% YoY to S/222 million (up 1% FXN). The company's Adjusted EBITDA Margin decreased 1.1p.p. to 21.4%. Adjusted Net Income improved to S/55 million from S/22 million in 1Q24. Peru showed strong performance, while Mexico faced challenges with market softness and operational setbacks. Colombia's results were impacted by provisions but showed encouraging signs in cash flow management. The company maintained a stable Leverage Ratio of 3.6x, improved from 4.3x in 1Q24. Currency depreciation significantly impacted results, with MXN/PEN down 22% and COP/PEN down 9%.

Auna (NYSE: AUNA), a Latin American healthcare company, has announced the pricing of $62.1 million in additional 10.000% senior secured notes due 2029. These Additional Notes will be issued under the same indenture as the company's existing $310.8 million notes issued in December 2023. The offering is private, targeting qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S. The Additional Notes will be guaranteed on a senior secured basis by certain Auna subsidiaries. The proceeds will be used to partially prepay debt under a November 2023 credit agreement and cover related expenses.